search
Back to results

The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive (JNJ-DEP)

Primary Purpose

Depression

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
JNJ-39393406
Placebo
Sponsored by
Tangent Data
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depression

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Meet DSM V criteria for history of MDD or BPD by MINI.
  2. Between 18-50 years of age, male or female subjects of any race, smokers and non-smokers.
  3. Able to provide informed consent. All participant patients must have signed an informed consent document indicating they understand the purpose of the study and the procedures required for the study and are willing to participate by complying with the study procedures and restrictions.
  4. Have a MADRS ≥ 10 and ≤ 34 and an YMRS < 7.
  5. In the opinion of the investigator, basic education and severity of symptoms (psychotic, negative, manic, agitation, depression) do not prevent the patient from attending to the cognitive tasks.
  6. In the opinion of the investigator the patient can be safely treated with no more than 2 psychotropic medications as background therapy (SOS for agitation and sleeping medication are allowed in addition to the 2 psychotropics).
  7. The background psychotropic(s) that will be continued through-out the 2 week trial must have been started at least 2 weeks prior to the baseline day at doses allowed by the local regulations and no changes in dose have been made during this pre-baseline 2 week period.
  8. Inpatients or out-patients at the discretion of the investigator (If outpatients the Readiness for Discharge Scale has to be administered at baseline and at each visit.)

Exclusion Criteria:

  1. Women of child bearing potential who do not practice contraception.
  2. Psychosis, florid manic or major depressive episode during the 4 weeks preceding baseline day or current psychosis.
  3. Patients on more than 2 psychotropic (hypnotics for sleep and occasional SOS for agitation do not count).
  4. Smokes more than 40 cigarettes per day.
  5. Unstable medical disease (malignancy, poorly controlled diabetes, or cardiomyopathy, serious pulmonary disease, kidney disease, impaired liver functioning. Particular attention should be given to exclude patients with ischemic heart disease).
  6. Has a clinically significant abnormal 12-lead electrocardiogram (ECG) at Screening Visit 1 as determined by the Investigator.
  7. At significant risk of committing suicide, or in the opinion of the Investigator, currently is at imminent risk of suicide or harming others.
  8. Patients with a current DSM-V substance or alcohol dependence.
  9. Concurrent delirium, mental retardation, drug-induced psychosis, or history of stroke, brain degenerative disorders and brain trauma.

Sites / Locations

  • Clinical Psychiatric Hospital
  • S.C. Stefi-Dent Srl
  • Hospital of Psychiatry and Neurology
  • Spit. Clinic de Urgenta Militar "Dr. Stefan Odobleja"

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

JNJ-39393406

Placebo

Arm Description

2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.

2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.

Outcomes

Primary Outcome Measures

To evaluate the effects of the nicotinic allosteric modulator JNJ-39393406 on cognition
Brief Assessment of Cognition (BACS)

Secondary Outcome Measures

To evaluate the effects of JNJ-39393406 on depressive symptoms
Montgomery-Asberg Depression Scale (MADRS)
To evaluate the effects of JNJ-39393406 on residual depressive symptoms
Brief Negative Symptoms Scale (BNSS)

Full Information

First Posted
January 21, 2016
Last Updated
May 20, 2020
Sponsor
Tangent Data
Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
search

1. Study Identification

Unique Protocol Identification Number
NCT02677207
Brief Title
The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive
Acronym
JNJ-DEP
Official Title
The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive Symptoms in 80 Patients With Unipolar or Bipolar Depression: a Phase II Exploratory add-on Double Blind Placebo Controlled 2 Week Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2018
Overall Recruitment Status
Completed
Study Start Date
February 2016 (undefined)
Primary Completion Date
May 2017 (Actual)
Study Completion Date
July 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Tangent Data
Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To evaluate the effects of the nicotinic allosteric modulator JNJ-39393406 on psychometric performance and residual depressive symptoms in patients who have been diagnosed with unipolar and bipolar depression but currently DO NOT meet criteria for an episode of Major Depression or Manic Episode.
Detailed Description
To evaluate the effects of the nicotinic allosteric modulator JNJ-39393406 on psychometric performance and residual depressive symptoms in patients who have been diagnosed with unipolar and bipolar depression but currently DO NOT meet criteria for an episode of Major Depression or Manic Episode. Hypothesis: Allosteric modulation of the a7nAChR with JNJ-39393406 improves psychometric performance and residual depressive symptoms in patients with unipolar major depression disorder (MDD) or bipolar depression (BPD). Outcome measurements: BACS MADRS BNSS CGI-S- BP, Questionnaire on smoking urges (QSU) and time to the first cigarette after waking up in the morning, Readiness for discharge scale.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
JNJ-39393406
Arm Type
Experimental
Arm Description
2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.
Intervention Type
Drug
Intervention Name(s)
JNJ-39393406
Intervention Description
JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
Primary Outcome Measure Information:
Title
To evaluate the effects of the nicotinic allosteric modulator JNJ-39393406 on cognition
Description
Brief Assessment of Cognition (BACS)
Time Frame
two weeks - each study visit
Secondary Outcome Measure Information:
Title
To evaluate the effects of JNJ-39393406 on depressive symptoms
Description
Montgomery-Asberg Depression Scale (MADRS)
Time Frame
two weeks - each study visit
Title
To evaluate the effects of JNJ-39393406 on residual depressive symptoms
Description
Brief Negative Symptoms Scale (BNSS)
Time Frame
two weeks - each study visit

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Meet DSM V criteria for history of MDD or BPD by MINI. Between 18-50 years of age, male or female subjects of any race, smokers and non-smokers. Able to provide informed consent. All participant patients must have signed an informed consent document indicating they understand the purpose of the study and the procedures required for the study and are willing to participate by complying with the study procedures and restrictions. Have a MADRS ≥ 10 and ≤ 34 and an YMRS < 7. In the opinion of the investigator, basic education and severity of symptoms (psychotic, negative, manic, agitation, depression) do not prevent the patient from attending to the cognitive tasks. In the opinion of the investigator the patient can be safely treated with no more than 2 psychotropic medications as background therapy (SOS for agitation and sleeping medication are allowed in addition to the 2 psychotropics). The background psychotropic(s) that will be continued through-out the 2 week trial must have been started at least 2 weeks prior to the baseline day at doses allowed by the local regulations and no changes in dose have been made during this pre-baseline 2 week period. Inpatients or out-patients at the discretion of the investigator (If outpatients the Readiness for Discharge Scale has to be administered at baseline and at each visit.) Exclusion Criteria: Women of child bearing potential who do not practice contraception. Psychosis, florid manic or major depressive episode during the 4 weeks preceding baseline day or current psychosis. Patients on more than 2 psychotropic (hypnotics for sleep and occasional SOS for agitation do not count). Smokes more than 40 cigarettes per day. Unstable medical disease (malignancy, poorly controlled diabetes, or cardiomyopathy, serious pulmonary disease, kidney disease, impaired liver functioning. Particular attention should be given to exclude patients with ischemic heart disease). Has a clinically significant abnormal 12-lead electrocardiogram (ECG) at Screening Visit 1 as determined by the Investigator. At significant risk of committing suicide, or in the opinion of the Investigator, currently is at imminent risk of suicide or harming others. Patients with a current DSM-V substance or alcohol dependence. Concurrent delirium, mental retardation, drug-induced psychosis, or history of stroke, brain degenerative disorders and brain trauma.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Davidson, M.D.
Organizational Affiliation
Principal Investigator
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinical Psychiatric Hospital
City
Codru
ZIP/Postal Code
MD2011
Country
Moldova, Republic of
Facility Name
S.C. Stefi-Dent Srl
City
Botosani
Country
Romania
Facility Name
Hospital of Psychiatry and Neurology
City
Brasov
Country
Romania
Facility Name
Spit. Clinic de Urgenta Militar "Dr. Stefan Odobleja"
City
Craiova
Country
Romania

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive

We'll reach out to this number within 24 hrs